Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

Video

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma (MCL). 

CAR T-cell therapy is a new ​therapeutic modality in MCL, so additional research is needed, says Wang.

In the phase 2 ZUMA-2 trial, it was discovered that certain cytokines are associated with efficacy and toxicity​, explains Wang. Moreover, future research efforts should aim to develop new measures that could enhance efficacy and minimize​ toxicity in these patients. 

As the ZUMA-2 trial was relatively small, larger studies are necessary to obtain further insight on​ the utility of minimal residual disease, as well as cytokine ​profiling, Wang concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.